On April 30, 2020 Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported it will host a conference call to provide updated data from patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Opdivo in its ongoing Phase 1/2 clinical trial (Press release, Replimune, APR 30, 2020, View Source [SID1234556802]). The investor event will be held on June 3, 2020. The Company will not be presenting data at the ASCO (Free ASCO Whitepaper) Annual Meeting this year, which has transitioned to a virtual format. The Company will provide additional details on the event at a later date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!